Skip to content
Delayed ~15 min

BKD BROOKDALE SENIOR LIVING INC

Health Care · Russell 2000

Next earnings: not announced yet

What 9 analyst firms say about BROOKDALE SENIOR LIVING INC: their latest ratings, price targets and how far the stock is from them. How it works

9.01 USD−1.80 (−16.65%) today
Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

+101.6%to the avg target 18.17 USD+9.16 USD
Buy 8 · Hold 0 · Sell 0

8 rated views · 9 analyst/firm records · 9 firms

Latest report10 Sep 2026avg report date 13 May
Target rangePrice is below every target

Radar score

  • Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8078
  • Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8056

Recent analyst activity · last 90 days

Our tracked history has 5 reports on BKD from 4 analyst firms in the last 90 days (9 firms in the past year).

Comparing each firm's latest target with its previous one: 1 lowered it and 1 left it unchanged.

No firm's latest available rating differs from its previous one.

Latest observed target change: Barclays lowered its target from $18.00 (set 3 Feb 2026) to $17.00 on 11 Aug 2026.

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

FirmAnalystLatest ratingReport dateLatest target (USD)
Bank of America SecuritiesJoanna GajukBuy6 Jan 202613.00 USD
BarclaysAndrew MokBuy10 Sep 202617.00 USD
CitigroupUnnamed analystBuy6 Jan 2026—
Compass PointRob SimoneBuy15 Jun 202622.00 USD
JefferiesBrian G TanquilutBuy22 Jan 202623.00 USD
RBC Capital MarketsBen HendrixBuy8 May 202617.00 USD
StephensRaj KumarBuy11 Aug 202617.00 USD
Weiss RatingsUnnamed analyst—24 Aug 2026—
Data feed RESEARCHResearch TeamBuy6 Oct 2026—

Partial coverage · checked 6 Nov (6 Nov 2026, 05:49 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.